PMID- 16365599
OWN - NLM
STAT- MEDLINE
DCOM- 20060201
LR  - 20191109
IS  - 1524-9557 (Print)
IS  - 1524-9557 (Linking)
VI  - 29
IP  - 1
DP  - 2006 Jan-Feb
TI  - Monoclonal antibodies targeted against melanoma and ovarian tumors enhance 
      dendritic cell-mediated cross-presentation of tumor-associated antigens and 
      efficiently cross-prime CD8+ T cells.
PG  - 41-52
AB  - Dendritic cells (DCs) constitute very attractive vectors for cancer immunotherapy 
      due to their ability to efficiently capture and present tumor antigens, which 
      initiates tumor-directed T-cell responses. Because the initiation of cytotoxic 
      anti-tumor immune responses requires the cross-presentation mechanism, antigen 
      targeting to DCs represents a very important step in the chain of events that 
      constitutes the cross-priming immune process. In the current study, we explored 
      the ability of DCs loaded with antibody-coated melanoma and ovarian carcinoma 
      tumor cells to cross-present tumor antigens to CD8+ T cells and elicit in vitro 
      anti-tumor immune responses. Coating melanoma and ovarian cancer cells with 
      monoclonal antibodies against different surface antigens (CD44, ME491, LFA-3, and 
      CD24) expressed by the tumor cells promoted the cross-presentation of the 
      tumor-associated antigens as MART-1, gp100, tyrosinase, and NY-ESO-1 by DCs to 
      CD8+ T. These tumor antigen-specific CD8+ T-cell populations resulting from the 
      DC-mediated cross-priming process were identified using specific immune tetramers 
      and were a few fold larger than the ones generated using peptide-pulsed or 
      apoptotic tumor cell-loaded DCs. The CD8+ T cells generated by DCs loaded with 
      monoclonal antibody-coated tumor cells were cytotoxic against the primary 
      melanoma and ovarian carcinoma cells. Thus, targeting monoclonal antibody-coated 
      tumor cells to DCs is a novel method that opens new perspectives for 
      immunotherapy strategies.
FAU - Cioca, Daniel Petru
AU  - Cioca DP
AD  - Immunology Department, Timisoara Medical University, Timisoara, Romania. 
      dcioca@personal.ro
FAU - Deak, Erika
AU  - Deak E
FAU - Cioca, Flavius
AU  - Cioca F
FAU - Paunescu, Virgil
AU  - Paunescu V
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Immunother
JT  - Journal of immunotherapy (Hagerstown, Md. : 1997)
JID - 9706083
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antigens, Neoplasm)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal/*immunology
MH  - Antigen Presentation/immunology
MH  - Antigens, Neoplasm/*immunology
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - Cross-Priming/*immunology
MH  - Dendritic Cells/*immunology
MH  - Female
MH  - Flow Cytometry
MH  - Humans
MH  - Immunohistochemistry
MH  - Male
MH  - Melanoma/*immunology
MH  - Middle Aged
MH  - Ovarian Neoplasms/*immunology
EDAT- 2005/12/21 09:00
MHDA- 2006/02/02 09:00
CRDT- 2005/12/21 09:00
PHST- 2005/12/21 09:00 [pubmed]
PHST- 2006/02/02 09:00 [medline]
PHST- 2005/12/21 09:00 [entrez]
AID - 00002371-200601000-00005 [pii]
AID - 10.1097/01.cji.0000175496.51594.8b [doi]
PST - ppublish
SO  - J Immunother. 2006 Jan-Feb;29(1):41-52. doi: 10.1097/01.cji.0000175496.51594.8b.